Eli Lilly, type 2 diabetes

Eli Lilly's weight-loss drug helps nearly 99% of patients remain diabetes-free
Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of weekly injections. The results suggest that tirzepatide - the active ingredient in Lilly's diabetes drug Mounjaro and weight-loss treatment Zepbound - could prevent one new case of diabetes for every nine patients treated.
99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly's Detailed Phase 3 Data Shows
Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.
Eli Lilly Say Most Tirzepatide Users Remained Diabetes-Free at 176 Weeks
Eli Lilly said new results from a Phase 3 study of its tirzepatide showed weekly injections in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss, with nearly 99% remaining diabetes-free at 176 weeks.
Lilly reports trial results of tirzepatide for treating obesity and pre-diabetes
Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide (Zepbound and Mounjaro) for treating pre-diabetic and obese individuals. Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type 2 diabetes (T2D) who were either obese or overweight with complications such as cardiovascular disease,
Hosted on MSN1d
Why Eli Lilly’s CEO says failing faster is essential to the company’s success
On this episode of Fortune’s Leadership Next podcast, host Diane Brady talks to Eli Lilly chair and CEO Dave Ricks. They ...
Verywell Health on MSN1h
Zepbound Cuts the Risk of Progressing to Diabetes by 94%, Eli Lilly Data Shows
Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...
Smart toilet, AI platform among tech in use at drugmaker Eli Lilly’s new $42m hub in S’pore
The centre will improve the quality of medical research and explore new medicine. Read more at straitstimes.com.
Amgen Rebounds. But Do Eli Lilly And Viking Therapeutics Now Have The Upper Hand?
Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral ...
24/7 Wall St1d
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 519.47% and ...
Drugmaker Eli Lilly opens $42m Digital Health Innovation Hub in S’pore aimed at drug discovery
Backed by the Economic Development Board (EDB), the hub was launched on Nov 14 at the Lilly Digital Health and Lilly Centre ...
Why Eli Lilly Is a No-Brainer Stock to Buy on the Dip
Even with this partial rebound, Lilly's share price remains roughly 13% below the peak set in late August. Some investors ...
Eli Lilly grows Milwaukee-area footprint with $40.8M warehouse acquisition — and more
Lilly (NYSE: LLY) makes drugs including Mounjaro for type 2 diabetes and Zepbound for obesity. For 2023, it reported $34 ...